Picard Medical, Inc., through its associated companies, is dedicated to the entire process of medical device commercialization, from initial design and manufacturing to production, distribution, marketing, and sales. A key product in its portfolio is the SynCardia TAH, a sophisticated total artificial heart specifically engineered to supplant a failing human heart in individuals afflicted with advanced cardiac disease. The firm's market presence extends across the United States, Europe, and other international regions. Established in 2021, Picard Medical maintains its primary operations in Tucson, Arizona, functioning as a direct subsidiary of Hunniwell Picard I, Llc.
Picard Medical Reports Second Quarter 2026 Financial Results
Picard Medical reported Q2 revenue of $3.0 million, up 39% year-over-year, with gross profit turning positive to $0.6 million.
Net loss narrowed 16% to $5.7 million, but the company required a 1-for-50 reverse stock split effective July 31 to maintain NYSE American listing compliance.
The NYSE accepted the firm's compliance plan in July, while the company advances its Emperor Total Artificial Heart platform through preclinical studies and conference presentations.